Beta Bionics Inc [BBNX] stock prices are up 0.45% to $22.23 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BBNX shares have gain 8.49% over the last week, with a monthly amount drifted -10.62%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Beta Bionics Inc [NASDAQ: BBNX] stock has seen the most recent analyst activity on October 01, 2025, when Goldman upgraded its rating to a Buy but kept the price target unchanged to $26 for it. Previously, Truist started tracking the stock with Buy rating on June 16, 2025, and set its price target to $26. On June 12, 2025, Lake Street initiated with a Buy rating and assigned a price target of $30 on the stock. Wolfe Research started tracking the stock assigning an Outperform rating and suggested a price target of $20 on May 30, 2025. Goldman initiated its recommendation with a Neutral and recommended $16 as its price target on May 30, 2025. Stifel started tracking with a Buy rating for this stock on February 24, 2025, and assigned it a price target of $25. In a note dated February 24, 2025, Piper Sandler initiated an Overweight rating and provided a target price of $26 on this stock.
The stock price of Beta Bionics Inc [BBNX] has been fluctuating between $8.89 and $26.66 over the past year. Currently, Wall Street analysts expect the stock to reach $21.5 within the next 12 months. Beta Bionics Inc [NASDAQ: BBNX] shares were valued at $22.23 at the most recent close of the market. An investor can expect a potential drop of -3.28% based on the average BBNX price forecast.
Analyzing the BBNX fundamentals
The Beta Bionics Inc [NASDAQ:BBNX] reported sales of 78.02M for trailing twelve months, representing a surge of 54.45%. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -0.8%, Pretax Profit Margin comes in at -0.94%, and Net Profit Margin reading is -0.94%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.41 and Total Capital is -0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.66 points at the first support level, and at 21.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.10, and for the 2nd resistance point, it is at 23.98.
Ratios To Look Out For
It’s worth pointing out that Beta Bionics Inc [NASDAQ:BBNX]’s Current Ratio is 14.68. Also, the Quick Ratio is 13.79, while the Cash Ratio stands at 1.8. Considering the valuation of this stock, the price to sales ratio is 12.39, the price to book ratio is 3.20.
Transactions by insiders
Recent insider trading involved Feider Stephen, Chief Financial Officer, that happened on Oct 03 ’25 when 4982.0 shares were sold. Chief Financial Officer, Feider Stephen completed a deal on Oct 01 ’25 to sell 15018.0 shares. Meanwhile, Officer Stephen Feider bought 4982.0 shares on Oct 03 ’25.
